SCHEMBL416290

SCHEMBL416290

CC(C)(C)OC(=O)NC12CCC(CC1)Cn1c2nc(C(=O)NCc2ccc(F)cc2)c(OS(C)(=O)=O)c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.39
TSHR P16473 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CYP2C9 P11712 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
NAMPT P43490 4/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
TP53 P04637 2/20 0.33
GLA P06280 1/20 0.33
POLB P06746 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
GNRHR P30968 1/20 0.33
KCNE1 P15382 1/20 0.32
CCR1 P32246 1/20 0.32
KCNQ1 P51787 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10144288 0.88 KCNH2 (0.47) KCNH2TSHRMEN1KMT2ALMNA
SCHEMBL419920 0.87 CYP2C9 (0.42) KCNH2TSHRMEN1KMT2ALMNA
SCHEMBL10143664 0.86 KCNH2 (0.40) KCNH2TSHRMEN1KMT2ALMNA
Hydrochloric Acid SCHEMBL420291 0.85 KCNH2 (0.39) KCNH2TSHRMEN1KMT2ALMNA
SCHEMBL10144297 0.85 KCNH2 (0.41) KCNH2TSHRMEN1KMT2ALMNA
Hydrochloric Acid SCHEMBL418376 0.84 KCNH2 (0.41) KCNH2TSHRMEN1KMT2ALMNA
SCHEMBL416417 0.83 KCNH2 (0.40) KCNH2TSHRMEN1KMT2ALMNA
SCHEMBL3780303 0.81 TP53 (0.39) KCNH2TSHRMEN1KMT2ALMNA
SCHEMBL63102 0.80 KCNH2 (0.47) KCNH2TSHRMEN1KMT2ALMNA
SCHEMBL63854 0.78 HTT (0.41) KCNH2TSHRMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022045-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS VENKATRAMAN SHANKAR (US) 2012-01-26 US disclosed
US-20120022045-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS VENKATRAMAN SHANKAR (US) 2012-01-26 US disclosed
WO-2010088167-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2010-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022045-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS CCND3, CDK3, CDK2 KCNH2 2502/4885TSHR 4412/4885MEN1 3274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.